Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | Treatment sequencing for metastatic castration-resistant prostate cancer

Mark Christopher Markowski, MD, PhD, Johns Hopkins Medicine, Baltimore, MD, discusses treatment sequencing for metastatic castration-resistant prostate cancer (mCRPC), which still remains to be determined, particularly with the introduction of newer experimental compounds such as lutetium PSMA. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.